PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   342 Trials   12240 News 


«12345678910111213...229230»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  AEBP1 restores osteoblastic differentiation under dexamethasone treatment by activating PI3K/AKT signalling. (Pubmed Central) -  Oct 3, 2024   
    Furthermore, LY294002 treatment decreased relative cell viability, Alizarin red staining, osteoblastic differentiation markers including OCN, OPN, RUNX2 and BMP, increased cell apoptosis rate and did not affect ALP staining in MC3T3-E1 cells under Dex treatment; meanwhile, LY294002 treatment weakened the effect of AEBP1 overexpression vectors on the above cell functions. AEBP1 restores osteoblastic differentiation under Dex treatment by activating the PI3K/AKT pathway.
  • ||||||||||  palazestrant (OP-1250) / Olema Pharma
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus (clinicaltrials.gov) -  Oct 2, 2024   
    P1,  N=155, Recruiting, 
    Our findings provide a theoretical basis for applying Sal to treat TNBC. N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026
  • ||||||||||  CRISPR-CAS9 KNOCKOUT SCREENING IDENTIFIES WRN AS AN ESSENTIAL GENE IN NEUROBLASTOMA () -  Oct 2, 2024 - Abstract #SIOP2024SIOP_1121;    
    N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026 The study systematically analyzes the NB-dependent epigenetic regulatory genes and identifies WRN as a critical biomarker for NB progression, thereby offering a potential therapeutic target for intervention in NB treatment.
  • ||||||||||  Piqray (alpelisib) / Novartis
    HRQoL, Symptom Severity, and Pain Among Patients Treated with Alpelisib for PROS (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1185;    
    P, P=N/A
    This real-world study provides important information from patients with PROS treated with alpelisib and their caregivers, including reported improvements in pain and functioning. These data complement those from EPIK-P1 (NCT04285723), wherein alpelisib demonstrated effectiveness and safety for the treatment of PROS, further supporting the clinical benefit of alpelisib for patients.
  • ||||||||||  ACTIVATED PI3K DELTA SYNDROME PRESENTING AS FAILURE TO THRIVE - A CASE REPORT (Monitor 11; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1155;    
    P3
    Overall, our study underscores the potential of flavonoids as therapeutic agents for RA and highlights the utility of integrative approaches combining network pharmacology, computational modeling, in silico methods, and pharmacokinetic assessment in drug discovery and development processes. Growth Curves Concerning for Failure to Thrive Patient
  • ||||||||||  LY294002 / Eli Lilly
    Journal, IO biomarker:  Role of PI3K/AKT signaling pathway involved in self-renewing and maintaining biological properties of chicken primordial germ cells. (Pubmed Central) -  Sep 28, 2024   
    Our findings indicated that although supplementation with the PI3K/AKT activator IGF-1 failed to promote proliferation under the assessed culture conditions, the PI3K/AKT inhibitor LY294002 resulted in retarded cell proliferation and reduced expression of germ cell-related markers...These findings indicated that the PI3K/AKT pathway is required for cell renewal, apoptosis, and maintenance of the reproductive potential in chicken PGCs. This study aimed to provide a theoretical basis for the optimization and improvement of a culture system for chicken PGCs and provide insights into the self-renewal of vertebrate PGCs as well as potential evolutionary changes in this unique cell population.
  • ||||||||||  LY294002 / Eli Lilly
    Journal:  LncRNA MALAT1 Expression Regulates Breast Cancer Progression via PI3K/AKT/mTOR Pathway Modulation. (Pubmed Central) -  Sep 26, 2024   
    The study also investigated the cross-talk of lncRNA MALAT1 and PI3K pathway genes by inhibiting it with PI3K inhibitor (LY294002) in MDA-MB-231 cell line...Moreover, the study proposes a mechanism of action of MALAT1, demonstrating that its inhibition can reduce the expression of the PI3K/AKT/mTOR axis. These findings emphasize the potential significance of targeting MALAT1 as a therapeutic strategy for breast cancer, and further exploration of this interaction is warranted to gain deeper insight into the molecular mechanism of this lncRNA.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  MEK inhibitors in oncology: a patent review and update (2016 - present). (Pubmed Central) -  Sep 26, 2024   
    The MEK1/2 inhibitors in combination with other kinase (BRaf/KRas/PI3K) inhibitors showed significant anti-proliferative activity. Other combination of MEK inhibitor with PD-1, DYRK1, EGFR, BTK and/or VEGF inhibitors etc. showed promising results in many cancers including colorectal, pancreatic, gastrointestinal, solid tumor, breast cancer, melanoma and multiple myeloma etc. The dual or multi-targeted approaches of these combinations showed better and precise treatment of patients with resistant cancer.
  • ||||||||||  LY294002 / Eli Lilly
    Preclinical, Journal:  PAR-2 gene expression data and morphology data of rabbit Achilles tenocytes stimulated with PDGF-BB in vitro. (Pubmed Central) -  Sep 23, 2024   
    Data on cell size, on F-actin immunohistochemical labeling intensity, ?-tubulin immunohistochemical labeling intensity and on cell aspect ratio (length of the cell divided by its width) are presented. Moreover, analogous to the first set of data, cytoskeletal rearrangement in the presence or absence of the inhibitors SB203580, LY-294002 and PD153035 in the presence or absence of PDGF-BB were assessed.
  • ||||||||||  LY294002 / Eli Lilly
    Journal:  TXNIP Regulates NLRP3 Inflammasome-Induced Pyroptosis Related to Aging via cAMP/PKA and PI3K/Akt Signaling Pathways. (Pubmed Central) -  Sep 20, 2024   
    Furthermore, we conducted experiments to modulate the improvement of TXNIP on NLRP3 inflammasome-induced pyroptosis, that is, the PI3K activator 740 Y-P and the PKA activator DC2797 inhibited the effect, while the PI3K inhibitor LY294002 and the PKA inhibitor H89 enhanced the effect. In conclusion, our study demonstrated that TXNIP regulates NLRP3 inflammasome-induced pyroptosis in HT-22 cells related to aging via the PI3K/Akt and cAMP/PKA pathways.
  • ||||||||||  Journal:  miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. (Pubmed Central) -  Sep 20, 2024   
    In conclusion, our study demonstrated that TXNIP regulates NLRP3 inflammasome-induced pyroptosis in HT-22 cells related to aging via the PI3K/Akt and cAMP/PKA pathways. In summary, we found that miR-30c-5p inhibited the proliferation, invasion and migration of ESCC by inhibiting PI3K/AKT signaling pathway for the first time, and this study is expected to provide a novel insight and potential therapeutic target for managing ESCC.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Brukinsa (zanubrutinib) / BeiGene, BGB-10188 / BeiGene
    Trial completion, Combination therapy, Monotherapy:  BGB-A317-3111-10188-101: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=97, Completed, 
    RES-lips may improve the sorafenib resistance in RCC, and the underlying mechanism may be related to the regulation of PI3K-AKT-mTOR and VHL-HIF signaling pathways. Active, not recruiting --> Completed
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
    P1/2 data, Journal:  Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. (Pubmed Central) -  Sep 17, 2024   
    P1
    These findings support further development of combined PI3K and histone deacetylase (HDAC) inhibition in TCLs and suggest a unique strategy to enable PI3K inhibitor-based combinations for additional patient populations. ClinicalTrials.gov identifier: NCT02783625 .
  • ||||||||||  Journal:  Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. (Pubmed Central) -  Sep 12, 2024   
    Furthermore, PI3K inhibition could effectively reverse Treg cells upregulation to enhance anti-tumor cytotoxicity of neoantigen-reactive T cells in vitro and reduce tumor growth in the xenograft gastric cancer model. Our study identified the CLDN18-ARHGAP fusion gene as a critical source of immunogenic neoepitopes, a key regulator of the tumor immune microenvironment, and immunotherapeutic applications specific to this oncogenic fusion.